$12.660
-0.555 (-4.38%)收盘时
MDWD 资讯
MDWD 事件
Company Reaffirms 2026 Revenue Guidance of $24-26 Million
The company said, "The Company reaffirmed its full-year 2026 revenue guidance of $24-26 million, supported by expected second-half contributions from the MSA and other government-funded programs."
MediWound Reports Q2 Revenue of $4.57M, Exceeding Expectations
Reports Q2 revenue $4.57M, consensus $2.59M. "In the second quarter, we continued to make meaningful progress with our two key programs," said Ofer Gonen, Chief Executive Officer of MediWound. "The EscharEx Phase III VALUE trial is advancing across the U.S., Europe, and Israel, with the interim sample size reassessment and completion of enrollment expected by the end of the first quarter of 2027. For NexoBrid, we strengthened the commercial opportunity through our new agreement with Vericel under its BARDA contract, which is expected to contribute to revenue in the second half of 2026."
MediWound Reports Q1 Revenue of $1.48M, Below Consensus
Reports Q1 revenue $1.48M, consensus $3.37M. "During the first quarter, we continued to advance both our strategic and operational priorities," said Ofer Gonen, CEO of MediWound. "Enrollment continues in the EscharEx's global Phase III VALUE study in venous leg ulcers, with more than 30 sites active across the U.S., Europe, and Israel. Enrollment has progressed more gradually than originally anticipated, and we have implemented targeted actions to support recruitment momentum. We continue to see strong engagement from investigators and strategic collaborators and remain encouraged by the growing medical and commercial interest in EscharEx."
MediWound and Vericel Sign $197M Contract
MediWound (MDWD) announced that Vericel (VCEL), its exclusive distributor of NexoBrid in North America, has been awarded a ten-year contract valued at up to $197M by the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Vericel reported that the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory system, design and validation of a U.S.-based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid. Vericel further reported that the base period contract of $35M includes approximately $10M over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries. According to Vericel, the ten-year contract, effective as of April 1, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S.-based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid.
Company Reaffirms Revenue Guidance of $24-26 Million for 2026
The Company reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028. Guidance assumes continued support from BARDA and the U.S. Department of War. The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。